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ABSTRACT gp55-P is a dimeric membrane protein with a single transmembrane helix that is coded by the env gene of the
polycythemic strain of the spleen focus forming virus. gp55-P activates the erythropoietin (Epo) receptor through speciﬁc
transmembrane helix interactions, leading to Epo-independent growth of erythroid progenitors and eventually promoting
erythroleukemia. We describe the use of magic angle spinning deuterium NMR to establish the structure of the transmembrane
dimer of gp55-P in model membranes. Comparison of the deuterium lineshapes of leucines in the center (Leu396–399) and at the
ends (Leu385, Leu407) of the transmembrane sequence shows that gp55-P has a right-handed crossing angle with Leu399
packed in the dimer interface. We discuss the implications of the structure of the gp55-P transmembrane dimer for activation of
the Epo receptor.
INTRODUCTION
Activation of membrane receptors is a common strategy used
by retroviruses to induce cell proliferation. The polycythe-
mic strain of the spleen focus forming virus (SFFV) encodes
a dimeric transmembrane (TM) viral glycoprotein, gp55-P
(1–3), which is responsible for the initial proliferative stage
of erythroleukemia (1,4–8). gp55-P is able to induce cell
proliferation by constitutively activating the erythropoietin
(Epo) receptor (1,9–11), a member of the cytokine receptor
superfamily that regulates erythrocyte maturation (12).
Both gp55-P and the Epo receptor are integral membrane
proteins that span membrane bilayers with a single TM helix.
Both proteins are dimeric, and they interact with one another
to form a stable complex in the membranes of erythroid
progenitors infected by SFFV (9,13–16). Genetic studies
have shown that the TM domain and the small C-terminal
juxtamembrane region of gp55-P are required for complex
formation with the Epo receptor and signaling (1,12,17,18).
Moreover, these regions of gp55-P are required for
leukemogenicity (6,19). The observation that the interaction
between gp55-P and the Epo receptor involves their TM
sequences means that gp55-P interacts with the Epo receptor
in a distinctly different fashion from the Epo ligand, which
binds to the extracellular domain of the receptor.
Evidence for the role of the TM domain in the activation
of the Epo receptor comes from comparing variant strains of
the SFFV and from mutational studies on gp55-P. Both the
polycythemic (P) and anemic (A) strains of the SFFV induce
erythroleukemia in adult mice. However, only gp55-P causes
Epo-independent proliferation of hematopoietic cell lines
(8). Moreover, although both gp55-A and gp55-P are able to
speciﬁcally bind to the TM domain of the Epo receptor, only
gp55-P promotes proliferation and differentiation of early
erythroid progenitors, the burst forming unit-erythroids (20).
These differences between gp55-A and gp55-P can be traced
to their TM sequences, which only differ at six positions
(6,8).
How do the six TM sequence differences between gp55-P
and gp55-A lead to functional differences between these two
similar viral proteins? In principle, the sequence differences
may cause changes in how the TM helices interact with one
another within a gp55 dimer or in how the gp55 dimer in-
teracts with the Epo receptor dimer. Both gp55-A and gp55-
P are homodimers when expressed on the cell surface (21) as
a result of disulﬁde bond formation between cysteines in
their extracellular domains (2). However, only the TM
domain of gp55-P forms homodimers when assayed by the
ToxR chloramphenicol acetyltransferase reporter system
(21). This suggests that the ability of gp55-P to activate
the Epo receptor is related, at least in part, to the ability of
the TM sequence of gp55-P to mediate tight helix-helix in-
teractions.
The human Epo receptor is not activated by gp55-P.
However, mutation of a single amino acid (Leu238) in the TM
domain of the human receptor to serine, its counterpart in the
mouse, allows it to be activated by gp55-P (22). The con-
verse mutation (Ser238Leu) in the mouse receptor eliminates
its ability to be activated, indicating that Ser238 enables gp55-
P activation of either the human or mouse receptor. Based on
computational searches, we proposed that Met390 of gp55-P
interacts speciﬁcally with Ser238 to activate the receptor (22).
Mutation of Met390 to isoleucine (the amino acid at position
390 in gp55-A) eliminates the ability of gp55-P to activate
human (Leu238Ser) and mouse Epo receptors (22). In
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addition, the M390L mutation was reported to induce anemia,
rather than polycythemia (23). These observations suggest
that the sequence differences between gp55-P and gp55-A
also result in changes in speciﬁc TM contacts between gp55-
P/A and the Epo receptor.
Here, we use deuterium NMR spectroscopy in combina-
tion with magic angle spinning (MAS) to determine the
structure of the gp55-P TM dimer. The dimer structure pro-
vides a framework for establishing the mechanism for how
the TM region of gp55-P activates the Epo receptor, as well
as for understanding how sequence differences in mutant
viral proteins confer different phenotypes. Deuterium NMR
spectroscopy takes advantage of the sensitivity of deuterium
lineshapes to molecular motion (24–26). We have previously
shown that the motion of amino acids located in TM helix
interfaces is restricted relative to amino acids oriented toward
the lipid membrane (27). As a result, by characterizing side-
chain motion as a function of the TM sequence, one can map
out the interface of interacting TM helices. Typically,
deuterium NMR lineshape analyses are carried out on static
samples and have been used extensively to study lipid mo-
tion (28). Studies of membrane proteins have been limited by
low sensitivity. To overcome this problem, we take advan-
tage of the increased sensitivity afforded by MAS to observe
changes in the quadrupolar lineshape. We propose that
deuterium MAS of consecutive leucine side chains in a TM
sequence provides a simple approach for studying helix-
helix interactions in membrane proteins. Together with
results from polarized infrared (IR) spectroscopy and compu-
tational searches, the deuterium MAS spectra of speciﬁcally
deuterated leucines in the TM sequence of gp55-P are used to
establish its TM dimer structure.
EXPERIMENTAL PROCEDURES
Materials
Deuterated (5,5,5-D3) leucine and deuterium-free water were purchased
from Cambridge Isotope Laboratories (Andover, MA). Other amino acids
and octyl-b-glucoside were obtained from Sigma Chemical (St. Louis, MO).
DMPC was obtained from Avanti Polar Lipids (Alabaster, AL) as a lyoph-
ilized powder and used without further puriﬁcation.
Peptide synthesis and puriﬁcation
Peptides (33 residues in length) corresponding to the TM domain of gp55-P
were synthesized using solid-phase methods at the W. M. Keck Peptide
Synthesis Facility at Yale University. The sequence is largely hydrophobic
with Arg and Trp/His deﬁning the N-terminal and C-terminal boundaries of
the TM domain, respectively.
The crude peptide (5–15 mg) was puriﬁed by reverse-phase high-
performance liquid chromatography on a C4 column using gradient elution.
The gradient starts with a largely aqueous solution of 70% distilled water,
12% acetonitrile, and 18% 2-propanol and is changed to a more hydrophobic
composition of 40% acetonitrile and 60% 2-propanol that elutes the
peptides. The elution was monitored by the optical absorbance at 260 nm.
The solutions corresponding to the peaks were collected into several frac-
tions that were then lyophilized and checked by mass spectrometry for
purity.
Puriﬁed gp55-P peptides were reconstituted by detergent dialysis by ﬁrst
dissolving DMPC, lyophilized peptide, and detergent (octyl-b-glucoside) in
triﬂuoroethanol. This mixture was incubated at 37C for over 2 h, and the
triﬂuoroethanol was removed by evaporation using a stream of argon gas
and then placing the sample under vacuum. The dry mixture was rehydrated
with phosphate buffer (10 mM phosphate and 50 mM NaCl, pH 7.4), such
that the ﬁnal concentration of octyl-b-glucoside was 5% (w/v). The re-
hydrated sample was then stirred slowly for at least 6 h, and the octyl-b-
glucoside was removed by dialysis using Spectra-Por dialysis tubing (3500
MW cut off) for 24 h against phosphate buffer at 37C. The samples were
then pelleted, lyophilized, and rehydrated with deuterium-depleted water (50
6 5% weight) and incubated at 37C for 24 h. The reconstituted membranes
were pelleted to form multilamellar dispersions and loaded into NMR rotors.
To characterize the inﬂuence of the hydration level on the deuterium
spectrum, parallel samples were run of Leu396 at 40% and 60% deuterium-
depleted water (by weight). The relative intensities of the MAS side bands
were not signiﬁcantly different between these samples (data not shown).
Polarized IR spectroscopy
Polarized attenuated total reﬂection (ATR) Fourier transform infrared (FTIR)
spectra were obtained on a Bruker IFS 66V/S spectrometer. Multilamellar
vesicle dispersions at a concentration of 10 mg lipid/mL were layered on
a germanium internal-reﬂection element using a slowﬂowof air directed at an
oblique angle to theATRplate to form an orientedmultilamellar lipid-peptide
ﬁlm. Each sample spectrum represents the average of 1000 scans acquired at
a resolution of 4 cm1.
The dichroic ratio (RATR) is deﬁned as the ratio between absorption of
parallel (Ak) and perpendicular (A?) polarized light (29). The observed
dichroic ratio is used to calculate the order parameter Smeas using the equation,
Smeas ¼
E2x  RATRE2y1E2z
E
2
x  RATRE2y  2E2z
¼ 3cos
2
u 1
2
 
3cos
2
a 1
2
 
Smem: (1)
Order parameters (Smeas) of 1.0 and 0.5 correspond to helical orien-
tations parallel and perpendicular to the membrane normal, respectively. The
order parameter depends on the electric ﬁeld amplitudes, Ex ¼ 1.399, Ey ¼
1.514, and Ez ¼ 1.621, in the thick ﬁlm limit which is applicable for our
experiments. u is the angle between the helix director and the normal of the
internal-reﬂection element, and a is the angle between the helix director and
the transition-dipole moment of the amide I vibrational mode.
To calculate the angle u between the helix director and the normal of the
ATR plate, one must know the value of the transition moment angle a. There
has been a wide range of values for a reported in the literature over the years
(e.g., from 20 (30) to 40 (31)) due to the lack of good model systems for
polarized IR studies where the orientation and disorder of the amide bonds
were known independently from the IR measurements. Recently, Marsh and
co-workers have converged on a value of a in two very different systems: 38
for a block co-polymer poly(g-methyl-L-glutamate)x-co-(g-n-octadecyl-L-
glutamate)y (32) and 39.5 for the membrane protein bacteriorhodopsin (33).
These results indicate that the transition moment angle for the amide I
vibration is independent of the speciﬁc system used. Importantly, Marsh and
Pali (33) show that there are only limited structural deviations between theTM
helices of bacteriorhodopsin and a standard a-helix. Consequently, the value
of 39.5 obtained for bacteriorhodopsin is applicable to standard helices.
We typically obtain polarized IR spectra of bacteriorhodopsin before
measurements on reconstituted TM peptides. This approach provides an
independent check of our experimental setup and validates the use of 39.5 for
the transition moment angle a. Bacteriorhodopsin is an integral membrane
protein that forms two-dimensional crystalline arrays that orient well on
germanium ATR surfaces. The disorder in orientation typically corresponds
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to an Smem of 0.8–0.9 based onmeasurements ofmosaic spread (30). Sincewe
cannot independently measure the disorder in the orientation of our recon-
stituted TMpeptides, we use a value of Smem equal to 0.85 as the upper limit in
our calculations.We assume that the disorder in the gp55-P sample is equal to
the disorder in bacteriorhodopsin. If the disorder is greater in our reconstituted
sample, then the measured dichroic ratio will be less than the true dichroic
ratio, and the true crossing angle will be smaller for the gp55-P helices.
One way to indirectly assess the quality of our reconstitutions is to
measure the dichroic ratios of the lipids. Dichroic ratios of the asymmetric
and symmetric lipid CH2 stretching modes at 2924 cm
1 and 2852 cm1
were 1.15 and 1.10, respectively, which correspond to order parameters of
0.65 and 0.67, and are consistent with well-oriented lipids (34).
NMR spectroscopy
Deuterium NMR spectra were obtained at a 2H frequency of 55.26 MHz
using MAS. MAS spectra yield much higher sensitivity compared to
conventional static spectra in membrane-reconstituted samples where the
concentration of deuterated peptide is low. A MAS frequency of 3 kHz was
used to have a sufﬁcient number of spinning side bands to deﬁne the static
lineshape. Single pulse excitation was employed using a 3.7-ms 90 pulse,
followed by a 4.5-ms delay before data acquisition. The repetition delay was
250 ms. A total of 600,000–800,000 transients were averaged for each
spectrum and processed using a 200-Hz exponential line broadening
function. Spectra were obtained at 25C.
MAS deuterium spectra were simulated using the program SIMPSON
version 1.1.0 (35) with a spin rate of 3.0 kHz. The asymmetry parameter, h,
was set to 1.0. Only the quadrupole coupling constant was varied to quantify
the breadth of the lineshape.
Computational searches
The computational search strategy using the program CHI has been
described previously (36). Low-energy conformations of helix dimers were
searched by rotating each helix through rotation angles f1 and f2 from 0 to
360with sampling step sizes of 25–45 and with interhelical separations of
9.5 A˚, 10.0 A˚, and 10.5 A˚. The f1 and f2 angles are equivalent to the a and
b angles originally described by Adams et al. (36). Molecular dynamics
simulations were run with simulated annealing at each rotational orienta-
tion of the dimer using the program X-PLOR along with the united atom
topology and parameters sets, TOPH19 and PARAM19, respectively.
Calculations were carried out for helices with both left-handed (LH) and
right-handed (RH) geometries with initial crossing angles of 25. Four
different runs were carried out for each starting geometry using torsional
angle dynamics. The rotation and crossing angles were allowed to vary
during the simulations. To maintain an a-helical conformation, distance
restraints were applied between Oi and Ni14 atoms along the backbone.
RESULTS AND DISCUSSION
Peptides corresponding to the TM domains of membrane
proteins are able to independently fold and associate in
membrane bilayers (37). To determine the structure of the TM
dimer of gp55-P, we ﬁrst establish that gp55-P TM peptides
adopt an a-helical TM conformation in bilayers using
polarized IR spectroscopy. Second, deuterium NMR spec-
troscopy of gp55-P containing speciﬁcally 2H-labeled leucine
is used to establish the rotational orientation and crossing
angle of the TM helices. Third, computational searches are
undertaken to generate possible low-energy dimer structures
that are consistent with the IR and NMR data.
TM a-helical structure of gp55-P
Fig. 1 presents polarized IR spectra of the TM domain of
gp55-P reconstituted into model dimyristoylphosphocholine
(DMPC) bilayers. The amide I vibration is observed at 1657
cm1, a frequency characteristic of a-helical secondary
structure. Fourier deconvolution of the amide I band reveals
no signiﬁcant nonhelical structure. The dichroic ratio of the
amide I band is sensitive to the orientation of the gp55-P
helix relative to the plane of membrane. The observed
dichroic ratio of 3.0 corresponds to a helix orientation of
;25 relative to the membrane normal (see Methods). These
data indicate that peptides corresponding to the gp55-P TM
domain are reconstituted into DMPC bilayers in a helical TM
conformation.
Deuterium MAS NMR of 2H-leucine as a probe of
TM helix interactions
There are several advantages of deuterium MAS spectros-
copy as a structural method for mapping out the helix
interfaces of oligomeric membrane peptides and proteins.
The ﬁrst advantage is that the NMR experiment used here is
simple. Only one-dimensional deuterium NMR spectra need
to be acquired. The pulse sequence consists of a single pulse
on the deuterium channel without proton decoupling.
Second, MAS greatly increases the sensitivity of the ex-
periment, which allows one to study peptides embedded into
membrane bilayers at low concentration. Moreover, the
MAS frequencies are slow and are readily attainable with
standard MAS probes. The third advantage is that the data
can be acquired over a broad temperature range, above and
below the lipid phase transition temperatures. In contrast,
distance measurements using rotational resonance or rota-
tional echo double resonance techniques are best done at low
temperature where the full dipolar couplings can be mea-
sured.
FIGURE 1 (A) Sequence of the TM domain of gp55-P. (B) Polarized IR
spectra of gp55-P TM peptides reconstituted into DMPC bilayers exhibit an
amide I vibration at 1657 cm1 and a dichroic ratio of 3.0. These data
indicate that the gp55-P TM domain has a-helical secondary structure with
the helix axis oriented roughly perpendicular to the membrane surface.
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Previous deuterium NMR studies of side-chain motion in
TM helices have focused on leucine (25), valine (27), and
alanine (26). Leucine containing a single deuterated methyl
group (5,5,5-2H-Leu) has several advantages over other
deuterated amino acids for probing molecular motion. First,
leucine is the most abundant amino acid in TM helices (38).
There are often strings of consecutive leucines in membrane
spanning sequences, allowing side-chain motion on different
faces of a helix to be compared in a sequential manner.
Second, leucine has a long ﬂexible side chain (Ca-Cb-Cg-
CD3). The high degree of ﬂexibility of the side chain results
in a large difference in the deuterium spectrum of leucine
restricted in a helix interface when compared to leucine
oriented toward a lipid interface. In contrast, the side chain of
alanine is much less ﬂexible. The alanine methyl group has
a deﬁned orientation relative to the helix backbone and is
only averaged by rotation about the Ca-Cb bond. For valine,
steric interactions between the side chain methyl groups and
the backbone restrict motion about the Ca-Cb bond. Only
subtle differences are observed in the lineshapes of valines
located in interfacial and noninterfacial positions (27).
The approach taken here is to compare spectra of
deuterated leucines at different positions in the gp55-P TM
helix in parallel samples. For instance, four consecutive
leucines (e.g., Leu396-Leu397-Leu398-Leu399) in the TM
sequence constitute one full turn of the gp55-P a-helix. At
least one of the leucine side chains will be facing the helix
dimer interface and exhibit a broader deuterium spectrum
due to restricted motion.
The intensities of the side bands in the MAS deuterium
spectra trace out the broad deuterium lineshapes. The high
ﬂexibility, which makes deuterated leucine a sensitive probe
of molecular motion, limits analyses of the deuterium
lineshape by detailed spectral simulation. To quantify the
observed differences in the width of these lineshapes, we
simulate the MAS deuterium spectra using the quadrupole
coupling constant as the only free parameter. The simulations
assume that the lineshapes have an asymmetry parameter
(h) of 1 due to high motional averaging (39). Importantly,
the simulations are simple to run using a program that
is readily available (http://nmr.imsb.au.dk/bionmr/software/
simpson.php).
Leu399 is in the gp55-P TM dimer interface
The strategy to determine the interface of the gp55-P dimer is
to target a consecutive stretch of leucines in the middle of
the TM domain: Leu396-Leu397-Leu398-Leu399. The string of
consecutive amino acids facilitates a direct comparison. The
left column of Fig. 2 shows the deuterium spectra of
the gp55-P TM peptides labeled at Leu396 through Leu399.
The large central resonance in the spectrum is due to residual
1H2HO. The sharp MAS side bands are spaced at the
spinning frequency (3 kHz) and trace out the envelope of the
deuterium lineshape. Comparison of the deuterium line-
shapes (i.e., the broad envelopes traced out by the intensities
of the MAS side bands) in Fig. 2 shows that the lineshape
of Leu399 is considerably broader than Leu396, Leu397, or
Leu398. The broader lineshape of Leu399 is indicative of
restricted motion compared to the other three leucines, which
in turn implies that Leu399 is located in the dimer interface.
Leu396 and Leu398 are more restricted than Leu397, consistent
with their packing against Leu399 (see structural model
below).
The width of the deuterium lineshape is modulated by
rotations about the Ca-Cb, Cb-Cg, and Cg-CD3 bonds of
leucine. The right column of Fig. 2 presents simulations of
the experimental 2H spectra that quantify the differences in
lineshape using an asymmetry parameter of 1.0 and varying
the quadrupolar coupling constant to obtain the best ﬁt to the
observed side band intensities. Based on the simulations,
Leu397 has the narrowest lineshape with a quadrupolar
coupling constant of 14 kHz, whereas Leu399 has the
broadest lineshape with a quadrupolar coupling constant of
25 kHz.
The gp55-P TM dimer has an RH crossing angle
Comparison of the deuterium spectra in Fig. 2 indicates that
Leu399 is in the dimer interface of gp55-P. With a single
point of contact in the center of the TM sequence, one can
FIGURE 2 Deuterium MAS NMR spectra and simulations of gp55-P
deuterium labeled at Leu396-Leu399 (A–D). The MAS spectra were obtained
at 3 kHz and a temperature of 25C. Each spectrum represents the average of
600,000–800,000 transients. Exponential line broadening of 200 Hz was
applied. The simulations to the right were carried out using the program
SIMPSON version 1.1.0 (35). The MAS rate was set to 3 kHz, and the
asymmetry parameter was set to 1.0. The best ﬁts to the observed side band
intensities were obtained using quadrupole coupling constants of 16 kHz
(A), 14 kHz (B), 16 kHz (C), and 25 kHz (D).
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establish the full dimer interface if one knows whether the
helices cross with an LH or RH crossing angle. Both types of
conﬁgurations are common in membrane proteins (40). The
crossing angle of the two helices in the gp55-P dimer can be
determined based on deuterium spectra of leucines that are
positioned at the ends of the TM helices. If Leu399 is in the
interface and roughly at the crossing point of the two helices
in the center of the TM sequence, then the position of Leu385
and Leu407 with respect to the interface will depend on the
crossing angle (Fig. 3). If Leu399 is in an interfacial ‘‘a’’ or
‘‘d’’ position of an LH coiled coil, then Leu385 would lie
in an ‘‘a’’ or ‘‘d’’ position. In contrast, Leu407 would lie in
a ‘‘b’’ or ‘‘e’’ position outside of the dimer interface. In a
similar fashion, in an RH geometry with Leu399 in the
interface, Leu385 would be oriented toward the lipid and
Leu407 would lie in the dimer interface.
The left column of Fig. 4 compares the deuterium NMR
spectra of Leu385 and Leu407. The spectrum of Leu385 is
similar to that of Leu396, which is in a lipid-facing position,
whereas the spectrum of Leu407 is similar to that of Leu399 in
the dimer interface. The broader lineshape observed for
Leu407 is best ﬁt with a quadrupole coupling constant of 27
kHz. The lineshape is consistent with an RH geometry and
argues that the gp55-P remains helical through Leu407, which
is located in the short juxtamembrane sequence of the
protein.
Finally, the helix tilt determined from polarized IR
experiments supports the conclusion from the deuterium
NMR measurements that the gp55-P helices have an RH
crossing angle. Based on packing considerations alone, the
crossing angles for RH and LH helices predicted by Chothia
(41) are 52 and 123, respectively. The tilt angle of 25
relative to the bilayer normal, inferred from the amide I
dichroic ratio, corresponds to a crossing angle of ;50
consistent with an RH crossing geometry.
An important point to emphasize here is that the sign of
the crossing angle (i.e., RH versus LH) is determined from
the NMR data presented in Fig. 4. Comparison of the Leu385
and Leu407 lineshapes is consistent with an RH crossing
angle but is not consistent with an LH crossing angle. An
estimate of the magnitude of the crossing angle is derived
from the polarized ATR-FTIR data. The calculated crossing
angle of;50 is consistent with the NMR determination that
the crossing angle is RH. However, as noted in the Methods
section the measured dichroic ratio corresponds to the
maximum tilt angle of the gp55-P helix. If the reconstitution
is not optimal, then the observed dichroic ratio may be lower
than the true dichroic ratio. This would yield a smaller
crossing angle for the gp55-P helices.
The deuterium MAS spectra and simulations also serve to
emphasize two additional points. First, the simulations
assume that the lineshapes have an asymmetry parameter
of 1. Both the Leu399 and Leu407 lineshapes exhibit spectra
where the 64 side bands have greater intensity than the 63
side bands. These features are well reproduced in the
simulations and support the assumption of h equal to 1.
Second, the Leu399 and Leu407 lineshapes are remarkably
similar. In both cases, the broadening of the lineshape is
attributed to restriction of leucine side-chain motion due to
packing in the gp55-P dimer interface. This suggests that
leucine motion and the associated deuterium MAS analyses
are not dependent on the position of the deuterated leucine
relatively to the membrane surface.
Structural model of the gp55-P TM dimer
The deuterium NMR data presented in Figs. 2 and 4 provide
structural constraints for evaluating models of the gp55-P
TM dimer that emerge from computational searches for low-
energy helix dimers (36). The NMR constraints were not
used to guide or otherwise inﬂuence the searches.
FIGURE 4 Deuterium MAS NMR spectra and simulations of gp55-P
deuterium labeled at Leu385 and Leu407. The MAS spectra were obtained at 3
kHz and a temperature of 298 K. The spectra of Leu385 (A) and Leu407 (B)
represent the average of 800,000 and 1,200,000 transients, respectively. An
exponential line broadening of 200 Hz was applied. The simulations to the
right were carried out using the program SIMPSON version 1.1.0 (35). The
MAS rate was set to 3 kHz, the asymmetry parameter was set to 1.0, and
the quadrupole coupling constant was changed to 16 kHz and 27 kHz to ob-
tain the best ﬁt to the side band intensities of Leu385 and Leu407, respectively.
FIGURE 3 Helical wheel plots for helix dimers having LH and RH
crossing angles. These diagrams have either 3.5 (LH) or 3.9 (RH) amino
acids per turn and provide a truer representation than a canonical helical
wheel diagram, of which amino acids line the dimer interface when helices
cross with LH or RH crossing angles, respectively. For example, in an LH
coiled coil, if Leu399 and Leu385 are in the dimer interface, then Gly391 and
Leu407 would lie outside of the interface.
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In our computational studies, low-energy conformations
of gp55-P helix dimers having both RH and LH crossing
angles were searched by rotating each helix in the dimer
relative to the other (see Methods). Fig. 5 A presents the
results of a computational search for RH crossing angles.
The ﬁgure shows only those structures that fall into a
‘‘cluster’’, where a cluster is deﬁned as a minimum of ﬁve
structures with a root mean square deviation of 1 A˚ or less.
These are the ﬁnal minimized conformations that have
migrated from their initial geometries into low-energy wells.
Of the initial 512 structures in the computational search, only
one symmetric cluster was found with Leu399 in the dimer
interface (circled in Fig. 5). The low-energy structure is
robust. Similar structures were found in simulations with
helix separations of 9.5 A˚, 10.0 A˚, and 10.5 A˚. The following
results are based on a helix-helix separation of 10.0 A˚.
The average molecular structure of the low-energy helix
dimer from the symmetric cluster is shown in Fig. 6 with
a helix crossing angle of ;35. The structure provides
a framework for interpreting mutational and biochemical
data on gp55-P. The working model is that a stable TM
dimer structure is required for activation and that amino
acids oriented away from the dimer interface interact directly
with the TM domain of the Epo receptor.
First, we discuss the amino acids predicted to mediate
dimerization of gp55-P. The helix interaction energy for the
average molecular structure in the symmetric cluster is
shown in Fig. 5 B. The low-energy structure is stabilized by
hydrogen bonding across the dimer interface of Thr384–
Thr384 and Thr388–Thr388. In simulations on gp55-P dimers
having shorter axial separations (e.g., 9.5 A˚), hydrogen
bonding of Ser392 to the backbone of Gly391 was also
observed. Decreasing the step-size during some of the
conformational searches also yielded clusters that exhibited
Gly391-Ser392 hydrogen bonding. The observation of Thr,
Ser, and Gly in the gp55-P interface is consistent with the
role of small and weakly polar amino acids in mediating
helix interactions in polytopic membrane proteins (42).
There are two sites in the gp55-P dimer interface, Gly391
and Leu399, where mutation blocks the ability of gp55-P to
activate the Epo receptor. Gly391 is predicted to be in the
dimer interface of the RH gp55-P structure (Fig. 3). Mutation
of Gly391 to leucine blocks the ability of gp55-P to activate
the Epo receptor (22). Glycine often serves as a molecular
notch for mediating TM helix interactions (43). For instance,
in the TM helix dimer of glycophorin A, two glycines are
found in the helical interface (29,44), and mutation of either
is sufﬁcient to disrupt dimerization (45).
FIGURE 5 Computational searches for low-energy structures of the gp55-
P TM dimer. (A) Low-energy structures of the gp55-P TM dimer with RH
helix crossing angles. The ﬁgure plots the ﬁnal rotational angles of the two
TM helices (f1 and f2) for those structures that fall into a ‘‘cluster’’. Only
a single cluster (circled) was observed along the diagonal and corresponds to
a symmetric dimer structure. No symmetric dimer clusters were observed for
comparable searches for gp55-P with LH crossing angles. The interhelical
separation for this search was maintained at 10 A˚. (B) Helix interaction
energies for average TM dimer structure from the symmetric cluster.
FIGURE 6 Structural model of the gp55-P TM dimer. (A) Cross section of
the gp55-P dimer showing the noninterfacial position of Leu385 (orange).
(B) Cross section of the gp55-P dimer highlighting one helix turn with four
consecutive leucines. Leu399 (red) is in the dimer interface.( C) Cross section
of the gp55-P dimer showing the interfacial position of Leu407 (orange). (D)
gp55-P TM dimer highlighting the leucine residues labeled in this study.
Met390, Trp405, and His408 are oriented away from the dimer interface.
Met390 is thought to interact with Ser298 of the Epo receptor.
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Mutation of Leu399 to isoleucine, the corresponding amino
acid in gp55-A, also abolishes the ability of gp55-P to
activate the Epo receptor (22). The deuterium data in Fig. 2
clearly show that Leu399 is well packed in the dimer
interface. Whereas the mutation of Leu399 to isoleucine is
conservative, in glycophorin A, it was found that mutation of
Leu75, which is in the dimer interface, to isoleucine was
sufﬁcient to disrupt dimerization (45). In the structural model
of the gp55-P dimer, replacement of isoleucine for leucine at
position 399 results in steric clash between the isoleucine
b-methyl groups. The effects of mutations at similar amino
acids in the dimer interfaces of gp55-P and glycophorin A
suggest that a stable gp55-P dimer structure is required for
activation of the Epo receptor.
The TM dimer structure of gp55-P in Fig. 6 shows that
several amino acids thought to mediate TM interactions with
the Epo receptor are oriented toward the lipid interface. We
have previously proposed that Met390 is oriented away from
the dimer interface and interacts with Ser238 in the Epo
receptor (22). Mutation of Met390 to isoleucine, the cor-
responding amino acid in gp55-A, abolishes the ability to ac-
tivate the Epo receptor (22). The gp55-P dimer structure
conﬁrms our previous proposal.
The isoleucine in position 404 is not directly in the dimer
interface and can tolerate substitution with Leu or Phe (22).
However, deletion of Ile404 results in loss of gp55-P-induced
activation of the Epo receptor (21). The gp55-P dimer
structure in Fig. 6 orients Trp405, a large aromatic amino
acid, away from the dimer interface. Deletion of Ile404 would
likely change the orientation of the C-terminal end of the
gp55-P helix such that Trp405 on opposing helices would
rotate toward the dimer interface and clash, possibly
disrupting dimerization or the local helical secondary
structure. These data suggest that the short C-terminal end
of gp55-P also interacts with the Epo receptor. This would
not be surprising because the juxtamembrane sequence of the
Epo receptor is highly conserved and has been proposed as
a switch region for regulating receptor activity (46). The
deuterium NMR data, showing that Leu407 is well packed in
the helical interface of gp55-P, provides compelling evi-
dence that the end of the gp55-P helix is not unraveled and
that both Trp405 and His408 are in a position to interact with
the juxtamembrane sequence of the receptor.
The low-energy structure of the gp55-P dimer along with
the analysis of the mutations above suggests that the gp55-P
dimer structure does not change upon interaction with the
Epo receptor. Rather, gp55-P catalyzes the conversion of an
inactive Epo receptor TM dimer to an active dimer.
Deuterium MAS NMR studies are in progress to directly
test this model.
Comparison of gp55-P and gp55-A suggests that novel
sequences may in principle be identiﬁed that could bind and
activate the Epo receptor to different extents. We plan to
exploit the productive interaction between the Epo receptor
and gp55-P TM domains as a selection system to design and
test sequences for their ability to bind the TM domain of the
Epo receptor and activate receptor signaling. Such genetic
systems have previously been described only for bacteria
(47–49) and could lead to new insights into speciﬁc TM
interactions in mammalian cell membranes.
Finally, the TM sequence of gp55-P is almost identical to
that of the fusiogenic envelope proteins of the mink cell
focus-inducing viruses and murine leukemia viruses. The
major exception is at position 392, where there is a conserved
proline in place of Ser in gp55-P and gp55-A (50). Position
392 is relatively tolerant to mutation in gp55-P (S. N.
Constantinescu, unpublished results). However, mutation of
Pro392 to alanine in the fusiogenic envelope proteins blocks
viral fusion with the cell membrane but not incorporation of
the envelope protein into virions (50). Langosch and co-
workers (51) have proposed that structural ﬂexibility
introduced by Pro392 is required for fusogenicity. The
structure of the gp55-P TM dimer provides a basis for under-
standing how small sequence differences in the TM domain
between gp55-P and the viral envelope proteins affect func-
tion. The gp55 proteins are not able to mediate membrane
fusion but have evolved the capability to activate membrane
receptors.
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